Imaging test for BCMA protein in people with multiple myeloma
Tests a PET scan that detects BCMA protein in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: 68Ga-BCMA PET/CT in Multiple Myeloma
Key facts
- Where
- Beijing, Jilin City, and Shijiazhuang, ChinaSee the 5 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07319897, who can take part
Where in China
- Beijing An Zhen Hospital of the Capital University of Medical SciencesBeijing, ChinaTaking people
- Beijing Tsinghua Changgung HospitalBeijing, ChinaTaking people
- Peking University First HospitalBeijing, ChinaTaking people
- First Hospital of Jilin UniversityJilin City, ChinaTaking people
- The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07319897
- Record updated
- 22 June 2026
- Original description
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.Read full original descriptionShow less
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.
Inclusion: patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse; patients with confirmed symptomatic MM; ability to understand and voluntarily sign written informed consent; ability to comply with study procedures; Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Exclusion: any other condition judged by the investigator to potentially interfere with study participation; pregnancy or lactation; inability to comprehend study procedures or cooperate with protocol requirements.